Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 803 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Addressing the Barriers to Minority Participation in Cancer Clinical Trials December 21, 2021 Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... May 20, 2020 Reunión anual de la American Society of Clinical Oncology de 2022:... June 7, 2022 FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... October 16, 2023 Load more HOT NEWS Community Surprises Teen Battling Bone Cancer With Brand New Car For... FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched...
